ACE inhibitor drug used to delay heart failure as effective in blacks as whites

July 18, 2002

DALLAS - July 17, 2002 - A drug widely used to treat patients with heart failure is as effective for black patients as it is for white patients, according to researchers at UT Southwestern Medical Center at Dallas.

The results of this analysis do not support the hypothesis that black patients with heart failure may not respond as well to angiotensin-converting enzyme (ACE) inhibitors as white patients with heart failure, said Dr. Daniel Dries, lead author of the study in today's issue of the Journal of the American College of Cardiology and assistant professor of internal medicine at UT Southwestern.

"Although the black participants responded equally well to the ACE-inhibitor as white participants, they still had overall increased rates of progression to heart failure," Dries said. "The precise explanation for the racial differences in the natural history of asymptomatic reductions in pump function is not known, but these data indicate that it is not explained by racial differences in response to ACE-inhibitor therapy."

A retrospective analysis of 4,054 study participants involved in the Studies of Left Ventricular Dysfunction (SOLVD) Prevention Trial found that enalapril, an ACE-inhibitor commonly given to patients with heart failure, is effective at reducing the development of heart failure in both population groups. Results of the SOLVD Prevention Trial were originally published in 1992 in The New England Journal of Medicine.

A 2001 report, in which Dries participated, suggested that enalapril was less effective in reducing the risk of hospitalization for heart failure in blacks compared to whites. There was no evidence for racial differences in enalapril's ability to reduce the risk of death. The analysis reported today focused specifically on the ability of ACE-inhibitor therapy to delay the development of heart failure in patients with asymptomatic reductions in heart function.

"The previous study found evidence for racial differences in response to ACE-inhibitor therapy only for a single clinical endpoint - the risk for hospitalization - which can be influenced by a variety of environmental and social factors," said Dries. "In this study, the benefit of enalapril was consistent and robust in reducing a spectrum of clinical endpoints indicating disease progression in both black and white participants."

Dr. Mark Drazner, a co-author of the study and assistant professor of internal medicine, said the present study showed that enalapril prevented the development of heart failure in black and white patients equally well.

"Coupling this with previous data showing that enalapril resulted in comparable reductions in mortality in black and white patients with heart failure, we believe that ACE-inhibitors should remain a cornerstone of therapy in patients with a weak or failing heart, irrespective of their race or ethnicity," Drazner said.

Dr. Mark Strong, assistant professor of internal medicine at UT Southwestern, also participated in the study.
-end-
The study was supported with funds from the National Institutes of Health, the American Heart Association, the Donald W. Reynolds Cardiovascular Clinical Research Center at UT Southwestern and the Doris Duke Charitable Foundation.

To automatically receive news releases from UT Southwestern via e-mail, send a message to UTSWNEWS-REQUEST@listserv.swmed.edu. Leave the subject line blank and in the text box, type SUB UTSWNEWS.

UT Southwestern Medical Center

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.